TY - JOUR
T1 - Sex-related differences in D-dimer levels for venous thromboembolism screening
AU - Reagh, Justin J.
AU - Zheng, Hui
AU - Stolz, Uwe
AU - Parry, Blair A.
AU - Chang, Anna M.
AU - House, Stacey L.
AU - Giordano, Nicholas J.
AU - Cohen, Jason
AU - Singer, Adam J.
AU - Francis, Samuel
AU - Prochaska, Jürgen H.
AU - Zeserson, Eli
AU - Wild, Philipp S.
AU - Limkakeng, Alexander T.
AU - Walters, Elizabeth L.
AU - LoVecchio, Frank
AU - Theodoro, Daniel
AU - Hollander, Judd E.
AU - Kabrhel, Christopher
AU - Fermann, Gregory J.
N1 - Funding Information:
Anna M. Chang has received funding personally from Abbott, Beckman Coulter, Stago Diagnostica, Entegrion, and Siemens as a clinical trial investigator. Stacey L. House has received funding personally from Diagnostica Stago, Inc., as a clinical trial investigator. Adam J. Singer has received funding personally from Alexion, Janssen, Pfizer, and Bristol Myers Squibb for consulting and participation in a speakers bureau. Jürgen H. Prochaska’s institution received grant funding from the Federal Ministry of Education and Research. Jürgen H. Prochaska has received funding personally from Bayer AG and Boehringer Ingelheim for lecturing. Philipp S. Wild's institution received grant funding from the Federal Ministry of Education and Research. Philipp S. Wild received funding personally from Boehringer Ingelheim, Sanofi‐Aventis, Bayer Healthcare, Daiichi Sankyo Europe, and Novartis as a clinical trial investigator. Philipp S. Wild has received funding personally from Boehringer Ingelheim, Bayer HealthCare, Evonik, AstraZeneca, and Sanofi‐Aventis for lecturing and consulting. Daniel Theodoro’s institution has received funding from the Emergency Medicine Foundation. Christopher Kabrhel's institution has received grant funding from Siemens Healthcare Diagnostics, Diagnostica Stago, and Grifols. Christopher Kabrhel has received funding personally from Boston Scientific for consulting as well as Salyx and Boston Scientific for participation on an advisory board.
Publisher Copyright:
© 2021 by the Society for Academic Emergency Medicine
PY - 2021/8
Y1 - 2021/8
N2 - Background: D-dimer is generally considered positive above 0.5 mg/L irrespective of sex. However, women have been shown to be more likely to have a positive D-dimer after controlling for other factors. Thus, differences may exist between males and females for using D-dimer as a marker of venous thromboembolic (VTE) disease. We hypothesized that the accuracy of D-dimer tests may be enhanced by using appropriate cutoff values that reflect sex-related differences in D-dimer levels. Methods: This research is a secondary analysis of a multicenter, international, prospective, observational study of adult (18+ years) patients suspected of VTE, with low-to-intermediate pretest probability based on Wells criteria ≤ 6 for pulmonary embolism (PE) and ≤ 2 for deep vein thrombosis (DVT). VTE diagnoses were based on computed tomography, ventilation perfusion scanning, or venous ultrasound. D-dimer levels were tested for statistical difference across groups stratified by sex and diagnosis. Multivariable regression was used to investigate sex as a predictor of diagnosis. Sex-specific optimal D-dimer thresholds for PE and DVT were calculated from receiver operating characteristic analyses. A Youden threshold (D-dimer level coinciding with the maximum of sensitivity plus specificity) and a cutoff corresponding to 95% sensitivity were calculated. Statistical difference for cutoffs was tested via 95% confidence intervals from 2,000 bootstrapped samples. Results: We included 3,586 subjects for analysis, of whom 61% were female. Race demographics were 63% White, 27% Black/African American, and 6% Hispanic. In the suspected PE cohort, 6% were diagnosed with PE, while in the suspected DVT cohort, 11% were diagnosed with DVT. D-dimer levels were significantly higher in males than females for the PE-positive group and the DVT-negative group, but males had significantly lower D-dimer levels than females in the PE-negative group. Regression models showed male sex as a significant positive predictor of DVT diagnosis, controlling for D-dimer levels. The Youden thresholds for PE patients were 0.97 (95% CI = 0.64 to 1.79) mg/L and 1.45 (95% CI = 1.36 to 1.95) mg/L for females and males, respectively; 95% sensitivity cutoffs for this group were 0.64 (95% CI = 0.20 to 0.89) and 0.55 (95% CI = 0.29 to 1.61). For DVT, the Youden thresholds were 0.98 (95% CI = 0.84 to 1.56) mg/L for females and 1.25 (95% CI = 0.65 to 3.33) mg/L for males with 95% sensitivity cutoffs of 0.33 (95% CI = 0.2 to 0.61) and 0.32 (95% CI = 0.18 to 0.7), respectively. Conclusion: Differences in D-dimer levels between males and females are diagnosis specific; however, there was no significant difference in optimal cutoff values for excluding PE and DVT between the sexes.
AB - Background: D-dimer is generally considered positive above 0.5 mg/L irrespective of sex. However, women have been shown to be more likely to have a positive D-dimer after controlling for other factors. Thus, differences may exist between males and females for using D-dimer as a marker of venous thromboembolic (VTE) disease. We hypothesized that the accuracy of D-dimer tests may be enhanced by using appropriate cutoff values that reflect sex-related differences in D-dimer levels. Methods: This research is a secondary analysis of a multicenter, international, prospective, observational study of adult (18+ years) patients suspected of VTE, with low-to-intermediate pretest probability based on Wells criteria ≤ 6 for pulmonary embolism (PE) and ≤ 2 for deep vein thrombosis (DVT). VTE diagnoses were based on computed tomography, ventilation perfusion scanning, or venous ultrasound. D-dimer levels were tested for statistical difference across groups stratified by sex and diagnosis. Multivariable regression was used to investigate sex as a predictor of diagnosis. Sex-specific optimal D-dimer thresholds for PE and DVT were calculated from receiver operating characteristic analyses. A Youden threshold (D-dimer level coinciding with the maximum of sensitivity plus specificity) and a cutoff corresponding to 95% sensitivity were calculated. Statistical difference for cutoffs was tested via 95% confidence intervals from 2,000 bootstrapped samples. Results: We included 3,586 subjects for analysis, of whom 61% were female. Race demographics were 63% White, 27% Black/African American, and 6% Hispanic. In the suspected PE cohort, 6% were diagnosed with PE, while in the suspected DVT cohort, 11% were diagnosed with DVT. D-dimer levels were significantly higher in males than females for the PE-positive group and the DVT-negative group, but males had significantly lower D-dimer levels than females in the PE-negative group. Regression models showed male sex as a significant positive predictor of DVT diagnosis, controlling for D-dimer levels. The Youden thresholds for PE patients were 0.97 (95% CI = 0.64 to 1.79) mg/L and 1.45 (95% CI = 1.36 to 1.95) mg/L for females and males, respectively; 95% sensitivity cutoffs for this group were 0.64 (95% CI = 0.20 to 0.89) and 0.55 (95% CI = 0.29 to 1.61). For DVT, the Youden thresholds were 0.98 (95% CI = 0.84 to 1.56) mg/L for females and 1.25 (95% CI = 0.65 to 3.33) mg/L for males with 95% sensitivity cutoffs of 0.33 (95% CI = 0.2 to 0.61) and 0.32 (95% CI = 0.18 to 0.7), respectively. Conclusion: Differences in D-dimer levels between males and females are diagnosis specific; however, there was no significant difference in optimal cutoff values for excluding PE and DVT between the sexes.
KW - D-dimer
KW - age-adjusted
KW - deep vein thrombosis
KW - diagnostic testing
KW - logistic regression
KW - pulmonary embolism
KW - receiver operating characteristic
KW - sex-adjusted
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85103630769&partnerID=8YFLogxK
U2 - 10.1111/acem.14220
DO - 10.1111/acem.14220
M3 - Article
C2 - 33497508
AN - SCOPUS:85103630769
SN - 1069-6563
VL - 28
SP - 873
EP - 881
JO - Academic Emergency Medicine
JF - Academic Emergency Medicine
IS - 8
ER -